Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Approach To Third Drug Class Expected Within Months

Executive Summary

FDA will include industry in the process of developing a distribution channel for drugs between the traditional prescription and over-the-counter spaces, agency representatives said at the Consumer Healthcare Products Association's Regulatory and Scientific Conference
Advertisement

Related Content

Risk Management Could Bolster FDA Behind-The-Counter Switches – Gottlieb
Risk Management Could Bolster FDA Behind-The-Counter Switches – Gottlieb
FDA Open To Behind-The-Counter NDAs While Mulling “Continuum” Class
FDA Open To Behind-The-Counter NDAs While Mulling “Continuum” Class
Draft Guidance Explains Inclusion Of Pharmacologic Class In New Labeling
The Third Way? Von Eschenbach Promotes Behind-The-Counter Drug Class
The Third Way? Von Eschenbach Promotes Behind-The-Counter Drug Class
Advertisement
UsernamePublicRestriction

Register

PS048378

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel